Amit Nilkanth Patel MD, BS, MS is an American-born-Indian cardiac surgeon and was director of clinical regenerative medicine and tissue engineering at the University of Utah in Salt Lake City. He was a tenured professor of surgery - cardiothoracic at the University of Utah until he left for the University of Miami. Dr. Patel left the University of Miami in May 2018. Patel studied medicine at the Case Western Reserve University. In 2002, he led a "breakthrough" study demonstrating that stem cell transplantation could treat congestive heart failure. He is currently the national lead investigator for Aastrom Biosciences now Vericel Corp to treat cardiomyopathy both ischemic and non-ischemic using adult stem cells in the U.S. He just completed and published the largest heart failure trial for cell therapy in patients with ischemic heart failure. The trial was published in the journal Lancet and demonstrated a 37% reduction in death and hospitalizations for patients with severe heart failure. He is also lead investigator for a number of trials to use adult stem cells to treat limb ischemia. He has taught many surgeons around the world in countries such as Thailand and India. Notable patients of his include Hawaiian singer Don Ho; Ho credited Patel's 2005 procedure on him with saving his life and allowing him to return to performing after being forced into retirement for health reasons. He is currently working on programs for type 2 diabetes, burn wound therapies with the U.S. military & arteriocyte, traumatic brain injury and plastic reconstruction. He has started collaborative programs in Peru, Argentina, Ecuador, Germany, and India. His newest program is to treat heart failure patients with one day out patient cell therapies – harvest. Patel has recently developed a stem cell spray for rapid healing of heart surgery and burns. He is also the founder of Xogenex LLC, a gene therapy company for heart failure. The project is code-names the "Bourne-Project" because it has multiple genes to improve heart function which can be regulated and non-virally integrated into patient. Currently the programis enrolling heart failure patients in the United States. Clinicaltrials.gov NCT03409627. He is also the co-founder of Jadi Cell LLC which involves a novel xenofree umbilical cord stem cell which is currently being used in a number of clinical trials. Patel was involved in a retracted study, authored with Mandeep R. Mehra and Sapan Desai, relating to using Hydroxychloroquine to treat COVID-19 during the 2020 pandemic, which used suspect data from Surgisphere. It was published in The Lancet which retracted it. He co-authored another COVID-19 study that also used suspect data from Surgisphere and which was retracted by New EnglandJournal of Medicine. Patel and Desai are related by marriage. In June 2020 both journals retracted the study, and the University of Utah terminated Patel's position. Dr. Richard Horton, editor in chief of The Lancet, called the paper a fabrication and "a monumental fraud". Dr. Eric Rubin, editor in chief of NEJM, said "We shouldn’t have published this".
